Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
OCC
vs
S
S&P/ASX 300
OCC
Over the past 12 months, OCC has underperformed S&P/ASX 300, delivering a return of -51% compared to S&P/ASX 300's 4% drop.
Stocks Performance
OCC vs S&P/ASX 300
Performance Gap
OCC vs S&P/ASX 300
Performance By Year
OCC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Orthocell Ltd
Glance View
Orthocell Ltd is an Australian medical technology company focused on repairing damaged soft tissue and nerves. It develops and commercialises products used by surgeons and specialist clinics to help treat tendon injuries, dental bone and gum defects, and peripheral nerve damage. Its best-known products are biologic implants and cell therapies that are designed to support healing rather than replace the tissue with metal or plastic parts. The company makes money by selling these medical products through hospitals, clinics, distributors, and licensing or commercial partnerships in different markets. Its customers are doctors, surgeons, and healthcare providers who use Orthocell’s products in procedures where natural healing is difficult or slow. Some of its offerings are made from collagen or a patient’s own cells, which makes the business more specialised than a typical medical device supplier. Orthocell sits in the regenerative medicine part of healthcare, where companies try to help the body rebuild injured tissue. That gives it a role somewhere between a device maker and a cell-therapy company: it does not just sell tools for surgery, but products meant to improve how the body repairs itself. This makes the business model tied closely to clinical adoption, regulatory approvals, and surgeon trust.